Nanoparticle‐based photothermal therapy for breast cancer noninvasive treatment
Y **ong, Y Rao, J Hu, Z Luo, C Chen - Advanced materials, 2023 - Wiley Online Library
Rapid advancements in materials science and nanotechnology, intertwined with oncology,
have positioned photothermal therapy (PTT) as a promising noninvasive treatment strategy …
have positioned photothermal therapy (PTT) as a promising noninvasive treatment strategy …
Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic
In the last decade, investigators have put significant efforts to develop several diagnostic
and therapeutic strategies against cancer. Many novel nanoplatforms, including lipidic …
and therapeutic strategies against cancer. Many novel nanoplatforms, including lipidic …
Traversing the diverse avenues of exopolysaccharides-based nanocarriers in the management of cancer
Exopolysaccharides are unique polymers generated by living organisms such as algae,
fungi and bacteria to protect them from environmental factors. After a fermentative process …
fungi and bacteria to protect them from environmental factors. After a fermentative process …
Recent progress and drug delivery applications of surface-functionalized inorganic nanoparticles in cancer therapy
Background Cancer remains a major global health burden and existing therapeutic
approaches face substantial challenges such as drug resistance, poor selectivity …
approaches face substantial challenges such as drug resistance, poor selectivity …
Lipid-engineered nanotherapeutics for cancer management
Cancer causes significant mortality and morbidity worldwide, but existing pharmacological
treatments are greatly limited by the inherent heterogeneity of cancer as a disease, as well …
treatments are greatly limited by the inherent heterogeneity of cancer as a disease, as well …
A comprehensive review of the biomaterial-based multifunctional nanocarriers for therapeutic applications in breast cancer
Breast cancer is among the most dreadful malignancies in women causing the highest
mortality across the globe. The prevalent therapies have not been able to be efficacious to …
mortality across the globe. The prevalent therapies have not been able to be efficacious to …
Fabrication of β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin inclusion complexes of Palbociclib: Physicochemical characterization, solubility enhancement, in …
P Paul, U Gupta, R Kumar, S Munagalasetty… - Journal of Molecular …, 2024 - Elsevier
Palbociclib (PAL) is an anti-cancer molecule that is highly selective for CDK4/6 inhibition
and approved for the management of advanced breast cancer. Due to its down-and-out …
and approved for the management of advanced breast cancer. Due to its down-and-out …
Oral linalool-based nanoemulsion of acalabrutinib for ameliorating its oral bioavailability and in vitro anticancer potential in T lymphoblast cell lines
A Shettiwar, U Gupta, E Chatterjee, B Patra… - Colloid and Polymer …, 2024 - Springer
Acalabrutinib (ACL) was approved in the United States in the year of 2017 and 2019 for the
treatment of chronic lymphocytic leukemia (CLL) and relapsed mantle cell lymphoma (MCL) …
treatment of chronic lymphocytic leukemia (CLL) and relapsed mantle cell lymphoma (MCL) …
Immune-modulating lipid nanomaterials for the delivery of biopharmaceuticals
S Kim, B Choi, Y Kim, G Shim - Pharmaceutics, 2023 - mdpi.com
In recent years, with the approval of preventative vaccines for pandemics, lipid nanoparticles
have become a prominent RNA delivery vehicle. The lack of long-lasting effects of non-viral …
have become a prominent RNA delivery vehicle. The lack of long-lasting effects of non-viral …
Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes
The present work aimed to develop and evaluate AmB-loaded nano-emulsion (AmB-NE)
which will augment the solubility of AmB and lead to enhanced anti-leishmanial activity. The …
which will augment the solubility of AmB and lead to enhanced anti-leishmanial activity. The …